Products
Viventia Biotech is building an enviable monoclonal antibody portfolio that may bring significant therapeutic potential for the treatment of many of the most common and deserving cancers.

Viventia Biotech has monoclonal antibody products in various stages of clinical and preclinical development, and continues to discover, screen and qualify numerous human monoclonal antibodies each year for addition to its antibody portfolio.



Copyright 2007 © Viventia Biotech Inc. All rights reserved.
The content of this site is for informational purposes only and is not intended to replace the advice of a health care professional.
Please consult your doctor if you have any questions regarding the information contained in this site.